Vaccine effectiveness against influenza A(H3N2) and B among laboratory‐confirmed, hospitalised older adults, Europe, 2017‐18: A season of B lineage mismatched to the trivalent vaccine
Open Access
- 5 February 2020
- journal article
- research article
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 14 (3), 302-310
- https://doi.org/10.1111/irv.12714
Abstract
Background Influenza A(H3N2), A(H1N1)pdm09 and B viruses co‐circulated in Europe in 2017‐18, predominated by influenza B. WHO‐recommended, trivalent vaccine components were lineage‐mismatched for B. The I‐MOVE hospital network measured 2017‐18 seasonal influenza vaccine effectiveness (IVE) against influenza A(H3N2) and B among hospitalised patients (≥65 years) in Europe. Methods Following the same generic protocol for test‐negative design, hospital teams in nine countries swabbed patients ≥65 years with recent onset (≤7 days) severe acute respiratory infection (SARI), collecting information on demographics, vaccination status and underlying conditions. Cases were RT‐PCR positive for influenza A(H3N2) or B; controls: negative for any influenza. “Vaccinated” patients had SARI onset >14 days after vaccination. We measured pooled IVE against influenza, adjusted for study site, age, sex, onset date and chronic conditions. Results We included 3483 patients: 376 influenza A(H3N2) and 928 B cases, and 2028 controls. Most (>99%) vaccinated patients received the B lineage‐mismatched trivalent vaccine. IVE against influenza A(H3N2) was 24% (95% CI: 2 to 40); 35% (95% CI: 6 to 55) in 65‐ to 79‐year‐olds and 14% (95% CI: −22 to 39) in ≥80‐year‐olds. Against influenza B, IVE was 30% (95% CI: 16 to 41); 37% (95% CI: 19 to 51) in 65‐ to 79‐year‐olds and 19% (95% CI: −7 to 38) in ≥80‐year‐olds. Conclusions IVE against influenza B was similar to A(H3N2) in hospitalised older adults, despite trivalent vaccine and circulating B lineage mismatch, suggesting some cross‐protection. IVE was lower in those ≥80 than 65‐79 years. We reinforce the importance of influenza vaccination in older adults as, even with a poorly matched vaccine, it still protects one in three to four of this population from severe influenza.Keywords
Funding Information
- Horizon 2020 Framework Programme (634446)
This publication has 39 references indexed in Scilit:
- Recent Trends in Hospitalization for Acute Myocardial Infarction in BeijingMedicine, 2016
- Influenza vaccines for preventing cardiovascular diseaseEmergencias, 2015
- Vaccines for the prevention of seasonal influenza in patients with diabetes: systematic review and meta-analysisBMC Medicine, 2015
- Impact of Repeated Vaccination on Vaccine Effectiveness Against Influenza A(H3N2) and B During 8 SeasonsClinical Infectious Diseases, 2014
- Influenza vaccines in immunosuppressed adults with cancerEmergencias, 2013
- Populations at risk for severe or complicated influenza illness: systematic review and meta-analysisBMJ, 2013
- Vaccines for preventing influenza in people with asthmaEmergencias, 2013
- Vaccines for preventing influenza in the elderlyEmergencias, 2010
- Impact of influenza vaccination on mortality risk among the elderlyEuropean Respiratory Journal, 2009
- Influenza vaccine for patients with chronic obstructive pulmonary diseaseEmergencias, 2006